Royal Bank Of Canada Reiterates $210.00 Price Target for Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) received a $210.00 target price from stock analysts at Royal Bank Of Canada in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 32.24% from the stock’s current price.

Other research analysts have also issued research reports about the stock. TheStreet raised shares of Jazz Pharmaceuticals PLC from a “c+” rating to a “b-” rating in a research note on Tuesday, March 28th. Piper Jaffray Companies set a $181.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Saturday, April 8th. Leerink Swann set a $179.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Thursday, April 27th. Sanford C. Bernstein set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the company a “market perform” rating in a research note on Monday, May 22nd. Finally, Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price objective for the company in a research note on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have given a buy rating to the stock. Jazz Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus target price of $182.64.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 1.25% during midday trading on Tuesday, hitting $156.81. 250,961 shares of the stock traded hands. The company has a market cap of $9.41 billion, a price-to-earnings ratio of 23.69 and a beta of 1.10. The stock has a 50-day moving average of $152.09 and a 200-day moving average of $135.76. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The business had revenue of $376.10 million during the quarter, compared to analysts’ expectations of $376.58 million. During the same period in the previous year, the business posted $2.26 EPS. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $11.00 earnings per share for the current fiscal year.

WARNING: “Royal Bank Of Canada Reiterates $210.00 Price Target for Jazz Pharmaceuticals PLC (JAZZ)” was originally published by Mideast Time and is owned by of Mideast Time. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.mideasttime.com/royal-bank-of-canada-reiterates-210-00-price-target-for-jazz-pharmaceuticals-plc-jazz/1814954.html.

In other news, SVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $152.56, for a total transaction of $30,512.00. Following the completion of the sale, the senior vice president now owns 22,562 shares in the company, valued at approximately $3,442,058.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Suzanne Sawochka Hooper sold 420 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $160.00, for a total transaction of $67,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 54,753 shares of company stock valued at $8,413,024 in the last 90 days. Insiders own 4.30% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares in the last quarter. World Asset Management Inc bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $205,000. Bridges Investment Management Inc. bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $208,000. Private Advisor Group LLC bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $215,000. Finally, Mn Services Vermogensbeheer B.V. increased its stake in shares of Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock valued at $217,000 after buying an additional 44 shares in the last quarter. Institutional investors and hedge funds own 86.34% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.